Researchers at Everist Genomics found a combination of five specific genes and gene expression levels present in a colorectal cancer tumor makes it high-risk and increases the risk of recurrence, according to a news release.
Using this data, Everist created the world's only molecular diagnostic test, OncoDefender-CRC, which can accurately identify tumors at high risk for recurrence among early-stage colon and rectal cancers. The test became commercially available in November, and the company has received physician requests for more than 1,000 specimen collection kits. Sanford Health Plan, which provides insurance in South Dakota, North Dakota, Iowa, Minnesota and Nebraska, has established a policy that will reimburse members for the test beginning in Jan. 2012.
Related Articles on Colorectal Cancer Screening:
Water Infusion for Cecal Intubation Increases Patient Tolerance, but not Intubation in Unsedated Colonoscopy
AGA Releases New Standards for Performing CT Colonography
Colonoscopy Best for Monitoring Mucosal Healing in Patients With Ulcerative Colitis
Using this data, Everist created the world's only molecular diagnostic test, OncoDefender-CRC, which can accurately identify tumors at high risk for recurrence among early-stage colon and rectal cancers. The test became commercially available in November, and the company has received physician requests for more than 1,000 specimen collection kits. Sanford Health Plan, which provides insurance in South Dakota, North Dakota, Iowa, Minnesota and Nebraska, has established a policy that will reimburse members for the test beginning in Jan. 2012.
Related Articles on Colorectal Cancer Screening:
Water Infusion for Cecal Intubation Increases Patient Tolerance, but not Intubation in Unsedated Colonoscopy
AGA Releases New Standards for Performing CT Colonography
Colonoscopy Best for Monitoring Mucosal Healing in Patients With Ulcerative Colitis